Trial Profile
A Phase IIa Efficacy and Safety Trial With Intravenous S95011 in Primary Sjögren's Syndrome Patients: An International, Multicentre, Randomised, Double-blind, Placebo-controlled Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Apr 2024
Price :
$35
*
At a glance
- Drugs Lusvertikimab (Primary)
- Indications Sjogren's syndrome
- Focus Therapeutic Use
- Sponsors Servier
- 02 Jun 2023 Status changed from active, no longer recruiting to completed.
- 22 May 2023 This trial has been completed in Germany and Hungary (End Date: 02 May 2023), according to European Clinical Trials Database record.
- 27 Apr 2023 According to an OSE Immunotherapeutics media release, main results are expected in the H1 2023.